The first U.S. commercial cases have been completed with the Abbott (NYSE: ABT)+
Aveir dual-chamber leadless pacemaker technology.

An advanced closed-loop anesthesia delivery system that monitors brain state to tailor propofol dose and achieve exactly the desired level of unconsciousness could reduce post-op side effects.

Johnson & Johnson MedTech’s (NYSE: JNJ)+
Ethicon unit today debuted an AI-powered laparoscopic surgical simulation platform.

Scores on a quality-of-life scale improved and use of antiarrhythmic drugs fell after people underwent treatment with the device.

A cyberattack group known as BlackCat is threatening to release Henry Schein (Nasdaq: HSIC)+
data unless the medical device manufacturer and distributor pays a ransom.

An interim analysis of Penumbra’s Indigo aspiration system met its primary safety and efficacy criteria, according to data shared at the Vascular Interventional Advances Conference.

As little as 1% reduction in deep sleep per year for people over 60 years of age translates into a 27% increased risk of dementia, according to a study which suggests that enhancing or maintaining deep sleep, also known as slow wave sleep, in older years could stave off dementia.

ST. PAUL, Minn.–(BUSINESS WIRE)– Cardio Flow, Inc., a privately held commercial-stage medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), is pleased to announce the successful completion of its first commercial cases for its FreedomFlow® Orbital Atherectomy Platform following FDA clearance in late September.